In yesterday’s Wall Street session, Verrica Pharmaceuticals Inc (NASDAQ:VRCA) shares traded at $2.91, down -6.73% from the previous session.
VRCA stock price is now -59.85% away from the 50-day moving average and -52.58% away from the 200-day moving average. The market capitalization of the company currently stands at $123.44M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $10, Needham recently Upgraded its rating from Hold to Buy for Verrica Pharmaceuticals Inc (NASDAQ: VRCA). On March 22, 2023, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $10, while ‘RBC Capital Mkts’ rates the stock as ‘Outperform’
In other news, White Ted, PRESIDENT AND CEO sold 32,469 shares of the company’s stock on Jul 22 ’24. The stock was sold for $229,231 at an average price of $7.06. Upon completion of the transaction, the PRESIDENT AND CEO now directly owns 250,121 shares in the company, valued at $0.73 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 23 ’24, PRESIDENT AND CEO White Ted sold 154 shares of the business’s stock. A total of $1,075 was realized by selling the stock at an average price of $6.98. This leaves the insider owning 249,967 shares of the company worth $0.73 million. A total of 39.28% of the company’s stock is owned by insiders.
During the past 12 months, Verrica Pharmaceuticals Inc has had a low of $2.86 and a high of $11.41. The fifty day moving average price for VRCA is $7.247 and a two-hundred day moving average price translates $6.136275 for the stock.
The latest earnings results from Verrica Pharmaceuticals Inc (NASDAQ: VRCA) was released for 2024-03-31. The net profit margin was -625.06% and return on equity was -412.98% for VRCA. The company reported revenue of $3.83 million for the quarter, compared to $37000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 10240.54 percent.
